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S chizophrenia is one of the most disabling psychi-atric diseases [1 , 2].  Patients with schizophrenia 
develop cognitive impairment as well as positive and 
negative symptoms.  The cognitive impairment includes 
deficits in attention,  learning,  memory,  and social 
cognition.  These impairments mean that patients with 
schizophrenia experience varying levels of difficulty in 
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It is necessary to assess functional impairment when treating schizophrenia.  The World Health Organization 
Disability Assessment Schedule 2.0 (WHODAS 2.0) has been adopted as a measure of functional disability in the 
Diagnostic and Statistical Manual of Mental Disorders,  Fifth Edition.  This study was a secondary analysis from 
a cross-sectional study of health-related behaviors among patients with schizophrenia.  We examined the valid-
ity and reliability of the Japanese version of the 12-item WHODAS 2.0 when self-administered by such patients.  
Participants were 350 outpatients with schizophrenia from a psychiatric hospital.  The standard six-factor struc-
ture of the WHODAS 2.0 showed a good fit for these participants.  The Cronbach’s alpha coefficient was 0.858,  
showing good internal consistency.  The WHODAS 2.0 showed moderate correlations with the modified Global 
Assessment of Functioning and Kessler 6 scales (r = −0.434 and 0.555,  respectively).  The results of this study 
show that the Japanese version of the 12-item self-administered WHODAS 2.0 has good internal consistency 
and convergent validity among patients with schizophrenia.  Further exploration of the usefulness of WHODAS 
2.0 in clinical settings is needed.
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daily life [2 , 3].  In addition,  some patients with schizo-
phrenia whose psychotic symptoms have resolved have 
residual apparent functional impairment [2].  Therefore,  
both improvement of psychotic symptoms and func-
tional recovery are emphasized in the treatment and 
rehabilitation of patients with schizophrenia.
The Diagnostic and Statistical Manual of Mental 
Disorders,  Fifth Edition (DSM-5) does not mention the 
Global Assessment of Functioning Scale (GAF),  which 
had been used for the overall evaluation of function in 
psychiatric patients until the DSM-IV-TR.  The GAF 
was ultimately excluded because it lacked conceptual 
clarity and quantifiable psychometrics [4].  Instead,  the 
DSM-5 recommends using the World Health 
Organization Disability Assessment Schedule 2.0 
(WHODAS 2.0) for functional evaluation [4].  The 
WHODAS 2.0 was developed by the WHO to provide a 
standardized method of measuring health and disability 
across various cultures and in the context of any kind of 
disease [5].  The WHODAS 2.0 assesses disability expe-
rienced in the last 30 days in 6 domains: Cognition,  
Mobility,  Self-care,  Getting along,  Life activities,  and 
Participation.  Quantitative surveys have been con-
ducted in diverse cultural environments,  including 
among healthy individuals,  and the WHODAS 2.0 has 
been shown to be highly sensitive to change regardless 
of the subject’s social background [5].  The WHODAS 
2.0 is available in a 12-item version and a 36-item ver-
sion,  and can be interview-administered,  self-adminis-
tered,  or proxy-administered.  The 36-item interview 
version can be administered in about 20 min and the 
12-item interview version in about 5 min [5].
Previous studies from Spain,  Turkey,  and the 
United States have reported the validity and reliability of 
the 36-item version and a 32-item version (omitting 
four questions related to work/school) of the WHODAS 
2.0 in patients with schizophrenia [6-8].  In these stud-
ies,  the WHODAS 2.0 was reported to be valid and 
reliable,  and to have appropriate scaling characteristics 
to assess disability in patients with schizophrenia.  
Tazaki et al.  developed a Japanese-language version of 
WHODAS 2.0 (WHODAS 2.0-J) based on the English 
version using a translation and back-translation process 
[9].  They then examined the validity and reliability of 
the Japanese scale in older people with and without 
disabilities.  However,  to our knowledge,  no reports 
have examined the validity and reliability of the 
WHODAS 2.0-J in patients with mental disorders,  
including schizophrenia.  The 12-item self-administered 
version of the WHODAS 2.0 is easy to use in everyday 
clinical settings and would thus be a useful measure in 
this context if it proves valid and reliable in such popu-
lations.  Therefore,  the purpose of this study was to 
investigate the validity and reliability of the 12-item 
WHODAS 2.0-J (WHODAS 2.0-J-12) among patients 
with schizophrenia.
Materials and Methods
Research design. This study was a preplanned 
secondary analysis of the Study of Health Behavior in 
People with Schizophrenia (SHEAPS).  The SHEAPS 
was a cross-sectional study enrolled in the UMIN 
Clinical Trials Registry (UMIN000023874).  The pri-
mary objective of the SHEAPS was to investigate cancer 
screening and smoking behaviors among people with 
schizophrenia.  The secondary objective of the SHEAPS 
was to investigate the validity and reliability of the 
WHODAS 2.0-J-12 among patients with schizophrenia.  
Detailed methods of the SHEAPS were described in our 
previous paper [10].
Setting. SHEAPS participants were recruited 
from the outpatient department of the Okayama 
Psychiatric Medical Center.  Located in the downtown 
area of Okayama City,  this center provides outpatient 
and inpatient services for both acute and chronic 
patients with mental disorders.  With 252 beds and 
approximately 250 outpatient visits per day,  it is a core 
psychiatric hospital in Okayama prefecture.
Research subjects. 1. Selection Criteria. We 
recruited patients who met all our inclusion criteria as 
of April 1,  2016.  The inclusion criteria were: 1) aged 
20-69 years; 2) visited the Okayama Psychiatric Medical 
Center for at least 1 year,  and visited the hospital at least 
twice in the last 6 months as their primary psychiatric 
outpatient service; and 3) diagnosed by their current 
primary psychiatrists with schizophrenia or schizoaf-
fective disorder (but not other schizophrenia spectrum 
disorders) according to the DSM-5 [4].
2. Exclusion Criteria. We excluded patients who:  
1) had comorbid intellectual disabilities and could not 
answer the questionnaire; 2) had severe psychiatric 
symptoms such that study participation was judged 
inappropriate by their primary psychiatrists; 3) had a 
severe physical condition such that study participation 
was judged inappropriate by their primary psychia-
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trists; and 4) could not read or write Japanese.
3. Procedure. In accordance with the eligibility 
criteria,  680 patients were identified in advance as 
potential participants from their electronic medical 
records.  Then,  420 patients were randomly extracted 
from the pool of 680 patients using computer-generated 
random numbers.  In total,  420 subjects were invited to 
participate in SHEAPS from September to November 
2016.  Most subjects were asked to participate at the 
time of their outpatient visit.  The researcher provided 
support as needed for participants when responding to 
the questionnaire.  If participants had an attendant,  
they were instructed to answer the question themselves 
to avoid proxy-administered responses.  Those who 
could not be contacted in this manner were contacted 
by telephone and mail and invited to participate to 
increase the participation rate.
Variables. The following variables were collected 
using the questionnaire and participants’ medical 
records.  The questionnaire was self-administered,  but 
a researcher was available to support participants in 
answering the questionnaire as needed.
1. Demographic Variables. Gender and age were 
drawn from participants’ medical records.  Educational 
level (junior high school or below,  high school,  junior/
vocational college,  and university/college or above),  
employment status (regular employee,  other employ-
ment above minimum wage,  self-employed,  and 
unemployed),  marital status (married and unmarried),  
and living status (living alone,  living with family,  and 
living in a facility) were extracted from the question-
naire responses.
2. WHODAS 2.0 (12-item version, self-administered).
The 12-item self-administered version of the WHODAS 
2.0 comprises 2 questions in each of the six domains 
(Cognition,  Mobility,  Self-care,  Getting along,  Life 
activities,  and Participation).  The WHODAS 2.0 
assesses disability over the last 30 days.  Items are scored 
on a 5-point scale ranging from 0 = none to 4 = extreme/
cannot do.  The scores are summed to give a total score 
(0-48 points).  In this study,  we used the WHODAS 
2.0-J-12 developed by Tazaki et al.  [9].
3. GAF. The GAF evaluates an individual’s overall 
level of functioning including psychiatric symptoms and 
occupational and social functioning on a scale from 0 to 
100 [11].  Both the severity of mental symptoms and the 
severity of social and occupational functioning are 
assessed,  and the lower score is adopted as the GAF 
score.  The modified GAF (mGAF) was developed by 
Hall and has more detailed criteria and a more struc-
tured scoring system [12].  In this study,  we used the 
Japanese version of the mGAF developed by Eguchi et 
al.  [13].
4. K6. The K6 is a screening tool for evaluating 
nonspecific psychological distress,  including anxiety 
and depression [14].  It comprises 6 questions that 
assess psychological distress in the past 30 days.  The 
total possible scores range from 0 to 24,  with a higher 
score reflecting more severe psychological distress.  The 
Japanese version of the K6 was developed using a 
back-translation method and has been validated in peo-
ple aged 20 years or older [15].
Sample size. The number of participants in this 
study was set at 420 and the study participation rate was 
estimated at 60%.  The maximum number of partici-
pants that could be recruited within the period of this 
study was 420.
Ethical approval. This study was approved by the 
Okayama University Graduate School of Medicine,  
Dentistry and Pharmaceutical Sciences and Okayama 
University Hospital (receipt number KEN1608-010),  
and by the Okayama Psychiatric Medical Center 
(receipt number 27-38).  Potential participants were 
informed that they could refuse or withdraw from par-
ticipation in the study at any time.  All participants 
provided informed written consent before the study 
started.
Statistical analysis. This study used SPSS version 
22 (IBM,  Tokyo) for the data analyses.  The significance 
level was set at p < 0.05.  Patients with missing values 
were not excluded from analyses,  which were con-
ducted using all available information.  Distribution of 
WHODAS 2.0-J-12 scores was evaluated by obtaining 
the mean,  standard deviation (SD),  and percentage of 
patients for each score (score of 0 points as a floor effect,  
and a score of 4 points as a ceiling effect).  The fit of the 
standard six-factor structure model in this sample was 
evaluated by confirmatory factor analysis using SPSS 
Amos [5].  The chi-squared value,  degrees of freedom,  
goodness of fit index (GFI),  adjusted goodness of fit 
index (AGFI),  comparative fit index (CFI),  and root 
mean square error of approximation (RMSEA) were 
calculated to assess the fit of the model,  with GFI 
≥ 0.95,  AGFI ≥ 0.90,  CFI ≥ 0.97,  and RMSEA ≤ 0.05 
considered to represent good fit [16].  Cronbach’s alpha 
was calculated to assess internal consistency.  In the 
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additional analysis,  we calculated the Cronbach’s alpha 
stratified by mGAF score (score ≥ 51 = mild to moderate 
disability vs. score ≤ 50 = severe disability) [17].  
Spearman’s rank correlation coefficients were calculated 
to evaluate the convergent validity between the 
WHODAS 2.0-J-12,  the mGAF,  and the K6.  In this 
method,  correlation coefficient values below 0.4 are 
considered weak,  0.4-0.7 are considered moderate,  and 
> 0.7 are considered strong.
Results
In total,  907 patients met the selection criteria.  We 
excluded 227 patients: 73 with comorbid intellectual 
disabilities,  145 with psychiatric symptoms too severe 
to participate in this study,  2 with a physical status too 
severe to participate in this study,  and 7 who were 
unable to read or write.  The remaining 680 patients 
were pooled as potential study participants (Fig. 1).  Of 
the 420 patients randomly selected from the pool of 680 
patients,  350 (83.3%) participated in this study.  
Participants’ background characteristics are shown in 
Table 1.  Three participants who had visited a clinic 
other than the study site at the time of this study 
answered the questionnaire by mail.  Because these 
three participants did not visit the study site,  their cur-
rent mGAF score could not be assessed.
The WHODAS 2.0-J-12 score distribution is shown 
in Table 2.  All 350 participants responded to the 
WHODAS 2.0-J-12 and there were no missing values.  
For each item,  the proportion of participants who 
answered that they could do nothing at all (scored 4 
points) was 0.0-18.9%.  The proportion of participants 
who answered that there was no problem (scored 0 
points) for each item was 41.4-95.4%.
Confirmatory factor analysis was performed for the 
standard six-factor domains.  The model was rejected 
based on the chi-square test of model fit (110.519,  
df = 39,  p < 0.001).  The goodness of fit measures were:  
GFI = 0.950,  AGFI = 0.900,  CFI = 0.951,  and RMSEA 
(90% confidence interval) = 0.072 (0.057-0.089).  
Regarding the internal consistency of the WHODAS 
2.0-J-12,  the Cronbach’s alpha coefficient was 0.858.  
The Cronbach’s alpha coefficients excluding any one 
item ranged from 0.839 to 0.858 and were smaller than 
the Cronbach’s alpha coefficient for all 12 items.  In the 
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Patients who: had visited the outpatient clinic twice or more in the last 6 months; had visited 
for at least 1 year as at April 1, 2016; were diagnosed with schizophrenia or schizoaffective 
disorder; and were aged 20‒69 years　　　　　　　　　　　　　　　　　　　　 　(N = 907)
Excluded　　　　　　　　　　　　　　　　　　　　　　　　 　n = 227
• Comorbid intellectual disabilities　　　　　　　　　　　　　 　n = 73
• Psychiatric symptoms too severe to participate in this study　　n = 145
• Inability to read or write　　　　　　　　　　　　　　　　　 　n = 7
• Physical status too severe to participate in this study　　　　　n = 2
Eligible patients　　　　　 　n = 680
Randomly selected　　　　　n = 420 (100%)
Eligible but not recruited during the questionnaire survey period n = 16
• Psychiatric symptoms too severe　　　　　　　　　　　　　 　n = 13
• Physical status too severe　　　　　　　　　　　　　　　　 　n = 1
• Death　　　　　　　　　　　　　　　　　　　　　　　　　 　n = 2
Declined to participate　　　　　　　　　　　　　　　　　　 　n = 54
Analyzed sample　　　　　　n = 350 (83.3%) Fig. 1　 Sampling flow.
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Table 1　 Participant characteristics












　≤junior high school 47 13.4
　>junior high school but ≤high school 155 44.3
　>high school but ≤ junior/vocational college 83 23.7
　≥university or college 65 18.6
Employment status
　Regular employee 32 9.1







　Living alone 78 22.3
　Living with family 268 76.6
　Facilities 4 1.1
mGAF score (n=347＊) 53.1±14.4 20-88
K6 score 5.8±5.3 0-24
＊Three patients had transferred to a doctor at the time of the survey and could not be evaluated.  mGAF,  modified Global Assessment of 
Functioning; K6,  Kessler 6 scale; SD,  standard deviation.
Table 2　 Descriptive statistics for each item in the Japanese version of the 12-item self-administered World Health Organization 
Disability Assessment Schedule 2.0 (n=350)









S1 (Mobility) 0.67 1.12 66.3 14.9 8.6 6.3 4.0
S2 (Life activities) 0.63 1.01 62.0 23.1 8.6 2.3 4.0
S3 (Cognition) 1.07 1.32 48.6 21.4 13.1 7.7 9.1
S4 (Participation) 1.32 1.55 46.9 17.4 11.1 5.7 18.9
S5 (Participation) 1.02 1.07 41.4 27.7 20.9 8.3 2.0
S6 (Cognition) 0.38 0.82 77.4 12.6 6.0 2.9 1.1
S7 (Mobility) 0.87 1.28 60.9 13.1 10.6 9.1 6.3
S8 (Self-care) 0.20 0.67 89.7 4.3 3.4 1.4 1.1
S9 (Self-care) 0.07 0.39 95.4 2.9 0.6 1.1 0.0
S10 (Getting along) 0.64 0.98 62.6 19.1 12.6 3.4 2.3
S11 (Getting along) 0.68 1.09 63.1 18.9 8.9 5.1 4.0
S12 (Life activities) 1.22 1.47 49.1 16.6 10.6 10.9 12.9
SD,  standard deviation.
additional analysis,  the Cronbach’s alpha coefficient for 
participants with mGAF scores ≥ 51 was 0.819 and that 
for those with scores ≤ 50 was 0.854.
The correlations between the WHODAS 2.0-J-12 
and the mGAF and K6 are shown in Table 3.  The 
WHODAS 2. 0-J-12 was moderately correlated with the 
mGAF and K6 (r = −0.434 and 0.555,  respectively).  
Among the WHODAS 2.0-J-12 domains,  that of Life 
activities had a moderate correlation with the mGAF 
(r = −0.463).  The domains of Cognition,  Getting along,  
Life activities,  and Participation showed moderate cor-
relations with the K6 (r = 0.432,  0.466,  0.505,  and 
0. 506,  respectively).
Discussion
To our knowledge,  this was the first study to exam-
ine the validity and reliability of the WHODAS 2.0-J 
among patients with schizophrenia.  The self-adminis-
tered version of the WHODAS 2.0-J-12 showed good 
internal consistency in outpatients with schizophrenia.  
In addition,  there was a moderate correlation with the 
mGAF,  which is commonly used to assess disability,  
and the K6,  which is a measure of depression and anx-
iety.
Although the self-administered version of the 
WHODAS 2.0-J-12 showed no ceiling effects,  it showed 
floor effects in most items.  In particular,  most patients 
answered they had no problems in the two Self-care 
domain items: Washing your whole body (89.7%) and 
Getting dressed (95.4%).  A study of patients with 
schizophrenia aged 18-55 years in Spain that used the 
36-item interviewer-administered WHODAS 2.0 also 
reported a strong floor effect in the Self-care domain 
[6].  The WHODAS 2.0 may therefore not be sufficient 
to assess self-care in patients with schizophrenia because 
basic self-care may not be impaired.
The standard six-factor structure of the WHODAS 
2.0 was rejected based on the chi-square test of model 
fit,  but the model fit indices were within the acceptable 
or good range.  Therefore,  the model was shown to fit 
our sample.  Guilera et al.  reported that the six-factor 
model of the 36-item version of the WHODAS 2.0 
showed good fit in patients with schizophrenia [6].  It is 
quite possible,  then,  that the 6-factor model in the 
WHODAS 2.0 may adequately explain the structure of 
the disability in patients with schizophrenia.
In this study,  the Cronbach’s alpha coefficient was 
0.858,  indicating good internal consistency.  The 
Cronbach’s alpha coefficient excluding any one item was 
smaller than that for all 12 items.  In addition,  the cor-
rected-item total correlation was greater than 0.3 for all 
items [18].  These results showed that all items were 
necessary.  A systematic review of studies examining the 
validity and reliability of the 12-item self-administered 
version of the WHODAS 2.0 reported Cronbach’s alpha 
coefficients of 0.85-0.95 for the general population [19].  
To our knowledge,  no previous studies have examined 
the internal consistency of the 12-item version of the 
WHODAS 2.0 among patients with schizophrenia.  For 
the 36-item interviewer-administered WHODAS 2.0,  a 
previous Spanish study reported a Cronbach’s alpha 
coefficient of 0.94 [6].  Therefore,  the WHODAS 2.0 
may be a reliable measure in patients with schizophre-
nia.  In addition,  the Cronbach’s alpha value stratified 
by mGAF score showed that the WHODAS 2.0-J-12 
had good internal consistency,  even in patients with 
severe symptoms and functional impairment.  This 
result suggested that the WHODAS 2.0-J-12 may be 
used regardless of case severity.
The self-administered version of the WHODAS 2.0-
J-12 showed a moderate correlation with the mGAF.  A 
previous study by Gspandl et al.  reported that the cor-
relation between the interview-administered WHODAS 
2.0 and GAF (score multiplied by −1) in outpatients 
with schizophrenia was r = 0.67 [20].  As our study used 
a self-administered version of the WHODAS 2.0,  it 
might be expected that the correlation observed in our 
study would be slightly weaker than that in the previous 
study by Gspandl et al.  In terms of the correlation 
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Table 3　 Correlations of the Japanese version of the 12-item 
self-administered WHODAS 2.0 with the mGAF and K6
mGAF K6





　Getting along -0.242＊＊ 0.466＊＊
　Life activities -0.463＊＊ 0.505＊＊
　Participation -0.313＊＊ 0.506＊＊
mGAF,  modified Global Assessment of Functioning; K6,  Kessler 6 
scale; WHODAS,  World Health Organization Disability Assessment 
Schedule.
＊p<0.01,  ＊＊p<0.001.
between each WHODAS 2.0-J-12 domain and the 
mGAF,  Life activities showed a higher correlation with 
the mGAF than other domains.  This was a reasonable 
result,  because the Life activities items are similar to the 
social functions assessed by the mGAF.  However,  in 
this study,  it was unclear whether the WHODAS 2.0-J-
12 was more strongly correlated with either psychiatric 
symptoms or social functions as reflected by the mGAF.
We found the self-administered version of the 
WHODAS 2.0-J-12 showed a relatively strong correla-
tion with the K6.  In particular,  the WHODAS 2.0-J-12 
domains of Cognition,  Getting along,  Life activities,  
and Participation showed moderate correlations with 
the K6 (Table 3).  However,  the domains of Mobility 
and Self-care showed low correlations with the K6.  This 
was consistent with the results of previous studies that 
examined the correlation between the WHODAS 2.0 
and depression as assessed by the Hamilton Depression 
Rating Scale [6 , 8].  It is reasonable that correlations 
between depression and Mobility or Self-care,  which 
primarily evaluate physical disabilities,  were lower 
compared with other domains.  Depression in schizo-
phrenia has been reported to be associated with worse 
daily functioning except for physical functioning,  and 
with health-related quality of well-being [21].  Although 
the present study cannot address the causal relationship 
between depression and functional impairment,  
patients with high depressive symptoms may not be able 
to adequately assess their own functional impairment.  
Therefore,  it may be necessary to assess depression 
when evaluating functional impairment in patients with 
schizophrenia.
The present study had several limitations.  First,  this 
study only evaluated the self-administered version of the 
WHODAS 2.0-J-12; the validity and reliability of other 
Japanese versions is unknown in patients with schizo-
phrenia.  Second,  this study only used the mGAF and 
K6 to examine convergent validity.  Third,  we did not 
assess the test-retest reliability and discriminant validity.  
Fourth,  this was a single-center study,  which limited 
the generalizability of the results.  However,  our study 
participants included patients with a range of severity,  
and the results of this study may be applicable to outpa-
tients with schizophrenia and those in general psychiat-
ric hospitals.  Fifth,  outpatients with very severe symp-
toms were excluded from this study,  which might have 
resulted in selection bias.  The self-administered version 
of the WHODAS 2.0 may be less valid and reliable in 
more severe patients as they may be unable to ade-
quately assess their own disability.  There may have been 
a further selection bias in that only those who chose to 
participate in the study could be included in the analy-
sis.
This study suggested that the self-administered ver-
sion of the WHODAS 2.0-J-12 had good internal con-
sistency and convergent validity in patients with schizo-
phrenia.  However,  some items (e.g.,  those included in 
the Self-care domain) with a strong floor effect may be 
less relevant for assessing disability related to schizo-
phrenia.  Further research and practice are needed to 
determine whether this scale is useful in treating and 
rehabilitating patients with schizophrenia in clinical 
practice.
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